CoreRx Welcomes David Vodak


CoreRx and Bend Bioscience are happy to announce the appointment of Dr. David Vodak as our new Chief Scientific Officer (CSO).

Dr. Vodak, a highly accomplished industry veteran, brings a wealth of expertise and strategic leadership to our scientific research and new technology development efforts. With expertise in drug delivery modalities including oral bioavailability enhancement, oral controlled release, and inhalation, David has a track record of bringing these technologies from idea to commercial application.

Having David join our team marks a significant milestone in CoreRx’s continued growth and commitment to enabling new therapeutics. His expertise adds a new dimension to our industry-leading product development offering.